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Fibromyalgia is considered as a combinationof physical,psychologicaland socialdisabilities.The causes ofpathologicmechanism
underlying ﬁbromyalgia are unknown, but ﬁbromyalgia may lead to reduced quality of life. The objective of this study was to
analyze the repercussions of craniosacral therapy on depression, anxiety and quality of life in ﬁbromyalgia patients with painful
symptoms. An experimental, double-blind longitudinal clinical trial design was undertaken. Eighty-four patients diagnosed with
ﬁbromyalgia were randomlyassignedto anintervention group (craniosacraltherapy) or placebo group (simulatedtreatment with
disconnected ultrasound). The treatment period was 25 weeks. Anxiety, pain, sleep quality, depression and quality of life were
determined at baseline and at 10 minutes, 6 months and 1-year post-treatment. State anxiety and trait anxiety, pain, quality of life
and Pittsburgh sleep quality index were signiﬁcantly higher in the intervention versus placebo group after the treatment period
and at the 6-month follow-up. However, at the 1-year follow-up, the groups only diﬀered in the Pittsburgh sleep quality index.
Approaching ﬁbromyalgia by means of craniosacral therapy contributes to improving anxiety and quality of life levels in these
patients.
1.Introduction
There is an increasing interest in the role of psychological
factors in ﬁbromyalgia, and studies have been published on
associated psychologicalvariables,psychopathologicalexpla-
nations, assessment instruments and psychological interven-
tion programs [1, 2]. Suhr (2003) considered psychological
factors to be important for understanding the subjective and
objective cognitive disorders of ﬁbromyalgia patients [3].
Various investigations have centered on the relationship of
ﬁbromyalgia with pain, depression, anxiety and quality of
life. The Copenhagen declaration in 1992 described psycho-
logicalpatterns frequently associated with ﬁbromyalgia, such
as anxiety and depression, and there is a growing interest in
this aspect among professionals of diﬀerent ﬁelds [4]. Nev-
ertheless, many authors consider that psychological factors
are more frequently the result than the cause of pain and dis-
ability in ﬁbromyalgia, and this issue remains controversial
[4].
Some symptoms of ﬁbromyalgia are similar to those ob-
served during depression, and antidepressants have been ad-
ministered to ﬁbromyalgia patients to treat sleep disorders
and pain symptoms [4]. Review of the literature on the asso-
ciation between ﬁbromyalgia and depression reveals two
divergentresearch lines. Hudson and others[5]b e l i ev et h a ta
direct association cannot be established between ﬁbromyal-
gia and depression, whereas Gruber and others (1996) [6]
propose a common etiology for ﬁbromyalgia and depres-
sion. Signiﬁcant diﬀerences in psychological state between
patients with ﬁbromyalgia and depression were reported in a
study on ﬁbromyalgia, pain intensity and duration and psy-
chological alterations; the results of depression and anxiety2 Evidence-Based Complementary and Alternative Medicine
questionnaires indicated that the somatic expression of de-
pression diﬀered between the two patient groups [7]. The
relationship between depression and ﬁbromyalgia remains
controversial. Although antidepressants can reduce pain and
fatigue in ﬁbromyalgia, the eﬀects of these drugs vary in
degree and duration among patients [7].
Various authors have indicated that patients with ﬁbro-
myalgia are more depressed than healthy controls and that
their perception of psychological distress or depression is
similar to that of depressed patients [8, 9]. Moreover, levels
of psychological distress (depression, anxiety) have been
correlated with cognitive ﬁndings in both groups of patients
(ﬁbromyalgia and depression) [10–12].
Garland [13] observed a higher degree of anxiety in ﬁ-
bromyalgia patients than in healthy controls or other groups
of patients with painful disease, for example, rheumatoid
arthritis. Anxious individuals usually have a respiratory dys-
function that generates more work in the upper chest, and
the resulting minimum diaphragmatic activity may exac-
erbate symptoms in patients with ﬁbromyalgia or chronic
fatigue syndromes. Although anxiety is known to be an
immediate symptom of hyperventilation, it is controversial
whether or not hyperventilation and anxiety in patients with
ﬁbromyalgia result from a broader alteration. In this context,
Peter et al. [14] reported that education to reduce the eﬀects
of hyperventilation can reduce ﬁbromyalgia symptoms,
including pain, fatigue and emotional distress.
Dysfunction of the autonomic nervous system may ex-
plain the diﬀerent clinical manifestations of ﬁbromyal-
gia. The hyperactive sympathetic nervous system of these
patients becomes incapable of responding to diﬀerent stress-
ing stimuli, which would explain the continuous tiredness
and the morning rigidity of these patients [15]. Likewise,
incessant sympathetic activity may explain the sleeping
disorders, anxiety, pseudo Raynaud’s phenomenon, dry syn-
drome and intestinal irritability [2, 15]. The other deﬁning
characteristics of ﬁbromyalgia such as diﬀuse pain, painful
sensitivitytopalpationandparesthesia mayalsobeexplained
by “sympathetically maintained pain”. This neuropathic pain
ischaracterizedbyaperceptionofpainregardless ofthepres-
ence of stimuli, accompanied by paresthesias and allodynia,
which are characteristic of patients with ﬁbromyalgia [16].
Patients frequently report sleeping disorders as well as
depression,andbothfactors are knowntohaveastrongasso-
ciation with cognitive disruption [17, 18]a n dt op l a ya n
important role in the reduced quality of life reported by
ﬁbromyalgia patients. There is a high prevalence of sleeping
problems in this population. In many cases, pain and fatigue
disappear with sleep. However, paradoxically, patients with
ﬁbromyalgia awake with intensiﬁed muscle rigidity, pain and
marked fatigue [19, 20]. Shaveret al. [21] described a vicious
circle of pain, poor sleep, fatigue and increased pain in overt
ﬁbromyalgia. Bigatti et al. [22] concluded that sleep predicts
subsequent pain in these patients but may be related to
depression due to pain and physical dysfunction.
The quality of life of patients with ﬁbromyalgia is espe-
cially impaired in relation to physical function, intellectual
activity and emotional state, inﬂuencing their working ca-
pacity and social relationships [23]. Backman [24]a ﬃrmed
that psychosocial factors are related to two dimensions ofex-
perience: psychological (cognitive, aﬀective) and social (in-
teracting with others, performing daily activities). According
to this author, psychosocial factors inﬂuence the perception
ofpain, which inturninﬂuencespsychologicalwellbeing and
social participation.
Various studies have demonstrated the eﬃcacy of bio-
feedback acupuncture to reduce pain symptoms in ﬁbromy-
algia[25–28].However,wecouldﬁnd nostudiesthataddress
the eﬀects of manual therapy on the autonomic nervous
systemorthepossiblebeneﬁtofthistypeofalternativethera-
pies as a complement to pharmaceutical treatment of hyper-
autonomic alterations and derived disorders (anxiety and
depression).Withthisbackground,theobjectiveofthisstudy
was to determine the eﬀects of craniosacral therapy on anxi-
ety, depression, pain, sleep qualityand qualityoflife inﬁbro-
myalgia patients up to 1-year post-treatment.
2.Methods
2.1. Setting and Participants. Patients with ﬁbromyalgia syn-
drome undergoing pharmaceutical therapy were recruited
from among members of the Almeria Fibromyalgia Asso-
ciation with clinical records at the Torrec´ ardenas Hospital
Complex (Almeria, Spain). Inclusion criteria were: diagnosis
of ﬁbromyalgia (by rheumatology specialist), age of 16–65
years and agreement to attend afternoon therapy sessions.
Exclusion criteria were: presence of physical disease, psycho-
logicaldisease,infection, fever,hypotension orskindisorders
or respiratory alterations that would limit the application of
the treatments.
Out of the 376 patients in the accessible population, 351
were subjected to a randomization procedure to recruit a
sample of 119 patients. Out of these 119 patients, 15 were
excluded, and the remaining 104 were randomly assigned by
means of a balanced stratiﬁed assignment to an intervention
(n = 52) or placebo (n = 52) group. The groups were
balanced for type of medication received, sex and age,
using a stratiﬁcation system that generates a sequence of
letters (from a table of correlatively ordered permutations)
for each category and combination of categories. Informed
consent was obtained from all participants according to
the ethical criteria established in the Helsinki declaration,
modiﬁed in 2000, for the performance of research projects.
In Spain, current legislation for clinical trials is gathered in
the Real Decreto 223/2004 February 6, 2004. This project
was approved by the research commissions of the University
of Almeria and of the Torrec´ ardenas Hospital Complex
(Almeria)-Servicio Andaluz de Salud (Andalusian Health-
care Service).
Twenty-one patients were under treatment with muscle
relaxants, 32 with antidepressants, 46 with anxiolytics, 59
with anti-inﬂammatories, 36 with corticoids and 84 with
analgesics.
2.1.1. Measurements. The following instruments were used
to measure anxiety, depression and quality of life in study
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(i) Visual analogue scale (VAS) for pain [29]: This scale
assesses the intensity of pain and degree of alleviation
experienced by the patient (0 = no pain, 10 = unbear-
able pain) [30].
(ii) Short form-36 health survey (SF-36) for quality of
life: The SF-36 survey evaluates dimensions of
functional state, emotional wellbeing and health.
Functional state dimensions are: physical function
(10 items), social function (two items), role limi-
tations due to physical problems (four items) and
role limitations due to emotional problems (three
items); emotional wellbeing dimensions are: mental
health (ﬁve items), vitality (four items) and pain
(two items); and health dimensions are: general
health perception (ﬁve items) and change in health
over time (one item—not included in ﬁnal score)
[31].
(iii) Pittsburgh Sleep Quality Index (PSQI): This ques-
tionnaire comprises 24 questions, 19 for subjects and
5 for individuals living with them. It yields scores for:
subjective sleep quality, sleep latency, sleep duration,
habitual sleep eﬃciency, sleep disturbance, use of
hypnotic medication and daily dysfunction. Each
component is scored on a scale of 0 to 3 (0 = no
problem, 3 = severe problem), yielding an overall
score range of 0–21 [32].
(iv) Assessment of the depression index (Beck depression
inventory): The Beckinventory is a self-applied ques-
tionnaire of 21 items that assesses a broad spectrum
of depressive symptoms. It gives weight to the
cognitive component of depression, with symptoms
in this area representing around 50% of the total
questionnaire score. Out of the 21 items, 15 refer to
ecological-cognitive symptoms, and six to somatic-
vegetative symptoms [33]. The score for each item
ranges from 0–3 (from least to greatest severity),
giving an overall score range of 0–63 points [34].
(v) State Trait Anxiety Inventory (STAI): This 40-item
questionnaire measures trait anxiety and state anx-
iety. For the trait anxiety scale (20 items), subjects
describe how they feel in general, and for the state
anxiety scale (20 items), how they feel at the present
time. A score is obtained for each scale [35].
2.1.2. Procedure. In this experimental, longitudinal double-
blind clinical trial, the intervention group was formed by 43
patients and the placebo group by 41. Before the treatments,
initial assessments of anxiety, depression, pain, sleep and
quality of life were performed in all patients [36]. Women of
childbearing age were assessed the day after their menstrual
period ended. These assessments were repeated at 30 min,
six months and 1 year after the last session of the 25-week
treatment program.
2.2. Intervention. The intervention group underwent a cran-
iosacral therapy protocol, with two weekly sessions of 1h
for 25 weeks. The treatment was carried out by an expert
craniosacral therapist with the patient in prone position.
This therapy consists of applying very mild manual traction
on cranial bones in ﬂexion or extension stages of the cran-
iosacral cycle. The aims were to contribute to re-establishing
the normal movement of cranial bones and to intervene in
the autonomic nervous system by releasing bone and mem-
branous restrictions [37]. Craniosacral therapy procedures
were: still point (occipital), compression-decompression of
temporomandibularjoint,decompressionoftemporalfascia,
compression-decompression of sphenobasilar joint, parietal
lift, frontal lift, scapular waist release and pelvic diaphragm
release [37–40].
The placebo group underwent two weekly 30-min ses-
sions of sham ultrasound treatment in which the discon-
nected probe (4 cm in diameter) was applied to the cervical
area (10 min), lumbar region (10 min) and both sides of the
knees (10 min). The sham treatment was performed with
the patient in prone position. The screen of the ultrasound
was covered to ensure that the patient was unaware that the
equipment was disconnected.
Both patient groups were instructed not to change
their pharmacological treatment during the 25-week study
period.
2.3. Statistical Analysis. The SPSS package(version17.0)was
used for the data analyses. After performing descriptive sta-
tistics of variables at baseline, the Kolmogorov–Smirnof
test was applied to evaluate the normal distribution of
variables. Continuous data were expressed as means ± SD.
Ap a i r e dt-test was used to examine changes in scores
between baseline and follow-up examinations. Inter-group
diﬀerences in variables were analyzed by using repeated-
measures analysis of variance. Relationships between demo-
graphic variables (sex and age group), aggravating factors,
work activity, diseases related to ﬁbromyalgia syndrome,
VAS pain score, dimensions of the SF-36 health survey for
quality of life, dimensions of the Pittsburgh sleep quality
index, total Beck depression inventory score and state and
trait anxiety scores were evaluated by calculating Pearson
correlation coeﬃcients. A 95% conﬁdence interval (CI) (α =
0.05) was considered in all tests.
3.Results
During the study, 9 patients withdrew from the intervention
group and 11 from the placebo group. Reasons for with-
drawal were death of spouse, start of another type of treat-
ment, change in pharmacologic therapy during treatment
period, and missing sessions due to acute pain crisis and
forgetfulness. The ﬁnal study sample comprised 84 patients
(81 females) aged 34–63 years with a mean age of 49.08 ±
14.17 years (Figure 1). There were no diﬀerences in baseline
demographic characteristics between the intervention group
(n = 4 3 )a n dp l a c e b og r o u p( n = 41) (Table 1). The groups
did not diﬀer signiﬁcantly in state anxiety (P < .320), trait
anxiety (P < .269) or VAS (P < .239) scores but diﬀered in all
dimensions of the SF-36 questionnaire with the exception of
vitality.4 Evidence-Based Complementary and Alternative Medicine
Initial sample (n = 119)
Excluded (n = 15)
Failure to meet inclusion criteria (n = 12)
Other reasons (n = 2)
Randomisation
Intervention group Placebo group
Assigned to intervention (n = 52)
Underwent the assigned
intervention (n = 43)
Assigned to intervention (n = 52)
Underwent the assigned
intervention (n = 41)
Follow-up during 25 weeks
of intervention
Follow-up during 25 weeks
of intervention
Analysed (n = 43) Analysed (n = 41)
Refusal to participate (n = 1)
Figure 1: Flow of participants in the study. None of the 84 participants reported adverse eﬀects.
Table 1: Baseline and demographic characteristics of study groups.
Characteristics Intervention (n = 43) Placebo (n = 41) P
Age mean (SD) 48.25 (13.34) 52.26 (10.98) .069
Sex (%)
Female 95.35 97.56 .529
Male 4.65 2.44 .052
Aggravating factors (%)
Emotional factors 100 100 1.000
Stress 42 50 .086
Work involving standing 46.32 49.48 .194
Cold 100 100 1.000
Work activity (%)
Full-time 12 18 .098
Part-time 34 26 .067
Sick leave 11 21 .051
Unemployed 43 35 .069
Diseases related to ﬁbromyalgia syndrome (%)
Arthritis 6.23 8.77 .119
Chorea 2.13 3.87 .201
Type I diabetes 3.25 5.75 .127
Type II diabetes 7 8 .845
Ulcerous colitis 6.5 3.5 .075
P = .05 between intervention and placebo groups.
In the whole study population, there were signiﬁcant
correlations at baseline between age and physical role (r =
0.412; P = .008), vitality and general health (r = 0.433;
P = .005), habitual sleep eﬃciency and social function (r =
0.319; P = .045) and between mental health and emotional
role (r = 0.346; P = .029), sleep duration (r = 0.485; P = .001)
and habitual sleep eﬃciency (r = 0.328; P = .039).
3.1.At35Weeksafter Intervention. At35weeks, theinterven-
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(P < .029) and trait anxiety (P < .042) versus baseline scores.
No changes were observed in the placebo group. The groups
diﬀered signiﬁcantly in trait anxiety (P < .045). Depression
scores did not diﬀer signiﬁcantly between groups or with
respect to baseline values (Figure 2).
VAS-measured pain improved signiﬁcantly in the inter-
vention group versus baseline (P < .035) and diﬀered be-
tweengroups(P<.041).Theinterventiongroupalsoshowed
signiﬁcant improvement in physical function (P < .024),
physical role (P < .020), body pain (P < .043), general health
(P < .039), vitality (P < .041) and social function (P < .029).
The placebo group showed no signiﬁcant changes versus
baseline in SF-36 questionnaire dimensions. The groups
diﬀered in physical function (P < .009), physical role (P <
.019), body pain (P < .036), general health (P < .048),
vitality (P < .046) and social function (P < .028) (Table 2).
The intervention group showed a signiﬁcant overall im-
provement in Pittsburgh sleep qualityindex score (P < .043),
and the groups diﬀered signiﬁcantly in the sleep duration
(P < .042) and sleep disturbance (P < .040) items (Table 3).
In the intervention group, signiﬁcant correlations were
found between trait anxiety and Beck depression inventory
score (r = 0.374; P = .027), overall SF-36 score and VAS score
(r =0.431;P =.015),andbetweenphysicalroleandVASscore
(r = 0.564; P = .021), body pain (r = 0.378; P = .016) and
mental health (r = 0.385; P = .024).
3.2.SixMonthsPost-Intervention. Nosigniﬁcant intra-group
or inter-group diﬀerences were found in state anxiety,
depression or pain with respect to baseline. The intervention
groupshowed asigniﬁcant improvement(versusbaseline)in
physical function (P < .041). The placebo group showed no
diﬀerences(versusbaseline) inany SF-36questionnaireitem.
The groups diﬀered signiﬁcantly in physical function (P <
.049) and vitality (P < .050). The groups also diﬀered signif-
icantly in sleep duration (P < .039), habitual sleep eﬃciency
(P < .047) and sleep disturbance (P < .045) (Table 4).
In the intervention group, correlations were found
betweenoverallSF-36questionnaire scoreandVASscore(r =
0.331; P = .048) and between trait anxiety score and Beck
depression score (r = 0.323; P = .045).
3.3. One Year Post-Intervention. At 1 year, the intervention
groupshowed asigniﬁcant improvement(versusbaseline)in
sleep duration (P < .040), habitual sleep eﬃciency (P < .044)
and daily dysfunction (P < .039) (Table 4). No signiﬁcant
diﬀerences in anxiety, depression, pain or quality of life were
found between groups or with respect to baseline values.
In the intervention group, trait anxiety was correlated
with Beck depression score (r = 0.311; P = .047).
4.Discussion
We examined the eﬃcacy of craniosacral treatment on anxi-
ety, depression and quality of life in patients with ﬁbromyal-
gia. At 6 months after a 25-week treatment period, patients
in the intervention group showed a signiﬁcant improvement
in their levels of state anxiety, trait anxiety, pain, quality of
life and Pittsburgh sleep quality index.
In comparative studies, patients with ﬁbromyalgia have
higher levels of depression in comparison to other patients
with chronic diseases. Bennet [41] found that 30% of
patientswithﬁbromyalgia presentwithdepressionattheﬁrst
consultation and 60% at some time in their clinical history.
These patients reported a diﬀuse non-localized pain that
tended to increase their level of depression.
Recent investigations have not considered depression to
be a primary symptom of ﬁbromyalgia, establishing that the
degree of depression measured by the Beck questionnaire is
closely related to the level of pain suﬀered by the patient
[42, 43]. Nonetheless, a variable percentage of ﬁbromyalgia
patients (30–70%) suﬀer depression, which is also present to
some degree in any chronic disease that courses with pain
[44]. In multicenter studies, symptoms of major depression
appear in 22–68% of patients aﬀected by ﬁbromyalgia,
anxiety in 16% and simple phobias in 12–16% [45]. It has
not been established whether these psychological disorders
are secondary to predominant ﬁbromyalgia symptoms or
are primary symptoms of the ﬁbromyalgia syndrome itself,
regardless of the remaining symptoms [46–48].
Quality of life results showed a signiﬁcant post-
therapeutic improvement in the physical role, body pain and
social function of the intervention group. These ﬁndings
are consistent with multidisciplinary studies in patients
with ﬁbromyalgia, which have underlined the importance of
motivation in achieving the participation of patients in the
diﬀerent therapy programs [49–52].
The improvement in physical function achieved by our
craniosacral therapy protocol was similar to that obtained by
aerobic exercise programs incombinationwith otherexercise
modalities and educational programs [53, 54]. Likewise, the
improvement obtained in the majority of SF-36 dimensions
was similar to that achieved after a 3-month hydrotherapy
program, which obtained a 40% reduction in the “body
pain” dimension, although the mechanisms underlying this
improvement have not been elucidated [55, 56].
T h ei m p r o v e m e n ti nt h eS F - 3 6q u e s t i o n n a i r eo fq u a l i t y
of life shown by intervention group patients was lesser than
their improvement in VAS score. This may be explained by
the greater sensitivity of the “body pain” dimension of the
SF-36 to detect painful changes in comparison to the VAS.
Redondo et al. [56] also reported signiﬁcant diﬀerences in
the results obtained by these two measures of body pain.
At the end of the treatment period, the intervention and
placebo groups diﬀered signiﬁcantly in overall Pittsburgh
subjective sleep quality index score and in habitual sleep
eﬃciency and sleep disturbance items. However, at one
month after therapeutic intervention, signiﬁcant diﬀerences
were also found in sleep latency and duration. These results
are in agreement with those published by Hains and Hains
[57] ,w h oa l s of o u n ds i g n i ﬁ c a n td i ﬀerences in sleep quality
at one month after a spinal compression and manipulation
protocol despite ﬁnding no changes in fatigue or pain
immediately after the treatment. An improvement in sleep
quality persisted for 1 year after a 20-session course of
manual therapy involving conjunctive tissue manipulation6 Evidence-Based Complementary and Alternative Medicine
Table 2: Diﬀerences in quality of life (SF-36 questionnaire) between study groups.
Baseline M (SD) P
Pre-T
25 weeks M (SD) P
1(a)-PT
6m o n t h sM (SD)) P
2(a)-PT
1y e a rM (SD) P
3(a)-PT S F - 3 6 I GP G I GP G I GP G I GP G
PF 49.43
(6.90)
51.90
(9.92) .199 45.90
(5.87)
50.53
(9.12) .009∗ 46.05
(4.61)
49.05
(8.03) .049∗ 47.43
(5.32)
50.68
(7.54) .367
PR 25.17
(6.88)
25.86
(7.35) .661 22.10
(6.84)
25.80
(6.98) .019∗ 23.85
(7.05)
25.47
(7.09) .067 24.67
(7.24)
26.01
(7.83) .121
BP 75.76
(7.20)
78.43
(12.75) .257 73.12
(6.08)
78.00
(13.07) .036∗ 74.25
(6.74)
78.65
(13.22) .052 74.84
(7.04)
77.39
(10.65) .234
GH 67.02
(4.25)
68.28
(6.84) .258 64.40
(4.65)
68.35
(6.39) .048∗ 66.02
(4.12)
67.92
(6.69) .087 66.72
(5.21)
67.63
(7.02) .321
V 60.05
(5.23)
58.90
(6.27) .376 62.73
(5.27)
59.48
(7.73) .046∗ 60.80
(5.11)
58.72
(7.78) .050∗ 61.34
(4.96)
59.01
(5.74) .201
SF 63.23
(7.12)
63.93
(12.41) .758 58.75
(6.74)
63.50
(11.57) .028∗ 59.85
(10.93)
63.05
(11.87) .075 60.45
(8.67)
64.45
(10.29) .067
RE 49.18
(7.65)
46.35
(5.69) .065 45.60
(7.85)
47.23
(5.66) .292 49.65
(6.52)
46.40
(5.96) .053 48.33
(8.31)
47.42
(7.29) .135
MH 76.65
(11.23)
80.60
(9.66) .097 77.48
(8.73)
81.15
(10.42) .069 74.15
(12.12)
77.80
(7.84) .074 75.64
(9.86)
79.45
(10.35) .083
Values are presented as means and standard deviations (SD). IG, intervention group; PG, placebo group; Pre-T, pre-therapy; 1(a) PT, post-therapy after 25
weeks of treatment; 2(a) PT, post-therapy at 6 months after end of treatment; 3(a) PT, post-therapy at 1 year after end of treatment; PF, physical function; PR,
physical role; BP, body pain; GH, general health; V, vitality;SF, social function; ER, emotional role; MH, mental health. ∗P = .05 (95% CI).
Table 3: Diﬀerences between study groups in Pittsburgh sleep quality index score at baseline and after therapy.
Baseline (n) P 25 weeks (n) P
IG PG Pre-T IG PG 1(a)-PT
PSQI NP MP SP NP MP SP NP MP SP NP MP SP
PSQ 0 12 31 2 13 26 .064 0 10 33 5 18 18 .043∗
SL 2 6 35 2 7 32 .948 0 22 21 1 12 28 .064
SD 1 12 30 2 5 34 .059 0 19 24 0 10 31 .042∗
HSE 1 15 27 0 10 31 .255 0 20 23 0 13 28 .065
SDI 0 17 26 3 14 24 .191 0 27 16 4 10 27 .040∗
D D03 4903 1 1 0 . 5 9 233 5502 9 1 2. 0 6 5
Values are shown as n = number of patients with no problems, moderate problems, severe problems. PSQI, Pittsburgh sleep quality index; IG, intervention
group;PG,placebo group;Pre-T, pre-therapeutic;1(a) PT,post-therapy(after25weeksoftreatment);PSQ,Pittsburghsubjectivequality;SL,sleeplatency;SD,
sleep duration; HSE, habitual sleep eﬃciency; SDI, sleep disturbance; DD, daily dysfunction; NP, no problems; MP, moderate problems; SP, severe problems.
∗P = .05 (95% CI).
Table 4: Diﬀerences between study groups in Pittsburgh sleep quality index at 6 months and 1 year after treatment.
6m o n t h s( n = number of patients) P 1y e a r( n = number of patients) P
IG PG 2(a)-PT IG PG 3(a)-PT
PSQI NP MP SP NP MP SP NP MP SP NP MP SP
PSQ 5 13 25 7 18 16 .093 4 11 28 6 19 16 .054
SL 4 18 21 2 14 25 .105 2 18 23 3 14 24 .132
SD 2 16 25 3 7 31 .039∗ 1 17 25 2 6 33 .040∗
HSE 4 19 20 0 14 27 .047∗ 2 20 21 0 13 28 .044∗
SDI 0 21 22 4 11 26 .045∗ 0 19 24 2 13 26 .088
DD 6 21 16 0 24 17 .240 3 18 22 1 28 12 .039∗
Values are shown as n = number of patients with no problems, moderate problems, severe problems. PSQI, Pittsburgh sleep quality index; IG, intervention
group; PG, placebo group; Pre-T, pre-therapy; 2(a) PT, post-therapy at 6 months after end of treatment; 3(a) PT, post-therapy at 1 year after end of treatment;
PSQ, Pittsburgh subjective quality; SL, sleep latency; SD, sleep duration; HSE, habitual sleep eﬃciency; SDI, sleep disturbance; DD, daily dysfunction; NP,
does not present problems; MP, moderate problems; SP, severe problems. ∗P = .05 (95% CI).Evidence-Based Complementary and Alternative Medicine 7
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Figure 2: Comparisons between study groups in levels of depression, anxiety and pain. ∗P = .05 (95% CI). Values are presented as means.
[58]. The release of fascial restrictions may improve sleep
quality by correcting visceral fascial dysfunction and thereby
favoring the secretion of platelet serotonin. A study of
the gut neurological system found that a high proportion
of ﬁbromyalgia patients had intestinal disorders, probably
due to neuro-endocrinal causes, which may aﬀect serotonin
secretion [59].
Studies on the eﬀects of aerobic exercise programs in ﬁ-
bromyalgia patients found no signiﬁcant diﬀerence in the
number of nights per week with sleep disturbances [60–
62]. However, multidisciplinary therapeutic programs were
reported to signiﬁcantly improve anxiety, depression, well-
being and sleep quality [43].
One of the limitations of the study was the inability to
study 25 of the 376 patients in the accessible population
before the randomized selection of the study group, due to
incompatibility with their work schedules. A further limita-
tion is related to the disparity between males and females8 Evidence-Based Complementary and Alternative Medicine
diagnosed with ﬁbromyalgia, which may be conditioned by
the cultural setting. It is also possible that subjects with less
severe pain were able to improve more rapidly.
5.Conclusions
The present study shows that craniosacral therapy improves
the quality of life of patients with ﬁbromyalgia, reducing
their perception of pain and fatigue and improving their
night rest and mood, with an increase in physical function.
Ourcraniosacraltherapyprotocolalsoreducesanxietylevels,
partially improving thedepressivestate.This manual therapy
modality must be considered as a complementary therapy
within a multidisciplinary approach to these patients, also
including pharmaceutical, physiotherapeutic, psychological
and social treatments.
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